Menu
ÚHKT

Impaktované publikace

[21]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Polakova, K.M.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

Erratum: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2015, impact factor 3.084 ]

[22]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Machova Polakova, K.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2013, impact factor 3.084 ]

[23]

Šmahelová, J.; Kaštánková, I.; Poláková, K.M.; Klamová, H.; Zemanová, K.; Tachezy, R.; Hamšíková, E.; Šmahel, M.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

[rok vydání 2017, impact factor 2.976 ]

[24]

Lopotová, T.; Žáčková, M.; Klamová, H.; Moravcová, J.

MicroRNA-451 in chronic myeloid leukemia: miR-451–BCR-ABL regulatory loop?

[rok vydání 2011, impact factor 2.923 ]

[25]

Moravcová, J.; Rulcová-Karavdić, J.; Broučková, A.; Klamová, H.

Effect of the duration and quality of peripheral blood sample storage on the results of qualitative and quantitative BCR-ABL transcript analyses in patients with CML

[rok vydání 2011, impact factor 2.923 ]

[26]

Petrackova, M.; Hamsikova, E.; Duskova, M.; Ptackova, P.; Klamova, H.; Humlova, Z.; Vonka, V.

Predictive value of serum cytokine levels in chronic myeloid leukemia patients

[rok vydání 2016, impact factor 2.860 ]

[27]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 2.806 ]

[28]

Koblihova, J.; Srutova, K.; Krutska, M.; Klamova, H.; Polakova, K.M.

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

[rok vydání 2018, impact factor 2.776 ]

[29]

Lopotová, T.; Nádvorníková, S.; Žáčková, M.; Polák, J.; Schwarz, J.; Klamová, H.; Moravcová, J.

N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia

[rok vydání 2012, impact factor 2.764 ]

[30]

Fuchs, O.; Provaznikova, D.; Kocova, M.; Kostecka, A.; Cvekova, P.; Neuwirtova, R.; Kobylka, P.; Cermak, J.; Brezinova, J.; Schwarz, J.; Markova, J.; Salaj, P.; Klamova, H.; Maaloufova, J.; Lemez, P.; Novakova, L.; Benesova, K.

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin´s lymphoma

[rok vydání 2008, impact factor 2.749]

[31]

Pavlík, T.; Janoušová, E.; Pospíšil, Z.; Mužík, J.; Žáčková, D.; Ráčil, Z.; Klamová, H.; Cetkovský, P.; Trněný, M.; Mayer, J.; Dušek, L.

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

[rok vydání 2011, impact factor 2.668 ]

[32]

Zackova, D.; Klamova, H.; Muzik, J.; Cmunt, E.; Racil, Z.; Machova Polakova, K.; Dvorakova, D.; Jurcek, T.; Razga, F.; Cetkovsky, P.; Dusek, L.; Mayer, J.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials

[rok vydání 2013, impact factor 2.605 ]

[33]

Racil, Z.; Razga, F.; Machova Polakova, K.; Buresova, K.; Polivkova, V.; Dvorakova, D.; Zackova, D.; Klamova, H.; Cetkovsky, P.; Mayer, J.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia : the role of different cell types

[rok vydání 2011, impact factor 2.580]

[34]

Rulcová, J.; Zmeková, V.; Zemanová, Z.; Klamová, H.; Moravcová, J.

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR

[rok vydání 2007, impact factor 2.561]

[35]

Fišer, K.; Klamová, H.; Moravcová, J.

Gene expression profiles in two accelerations in a CML patient

[rok vydání 2007, impact factor 2.483]

[36]

Machova Polakova, K.; Lopotova, T.; Klamova, H.; Moravcova, J.

High-resolution melt curve analysis : initial screening for mutations in BCR-ABL kinase domain

[rok vydání 2008, impact factor 2.390]

[37]

Lopotová, T.; Polák, J.; Schwarz, J.; Klamová, H.; Moravcová, J.

Corrigendum to "Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs" [Blood Cells Mol. Dis. 49 (1) (2012) 41-47] (DOI:10.1016/j.bcmd.2012.04.001)

[rok vydání 2013, impact factor 2.390 ]

[38]

Žáčková, M.; Moučková, D.; Lopotová, T.; Ondráčková, Z.; Klamová, H.; Moravcová, J.

Hsp90: a potential prognostic marker in CML

[rok vydání 2012, impact factor 2.390 ]

[39]

Moravcová, J.; Rulcová, J.; Polák, J.; Klamová, H.; Haškovec, C.; Zemanová, Z.

CML patient with rare b2a3 (e13a3) variant of BCR-ABL transcript : complete molecular response to imatinib.

[rok vydání 2006, impact factor 2.372]

[40]

Moravcova, J.; Rulcova, J.; Machova Polakova, K.; Klamova, H.

Control genes in international standardization of real-time RT-PCR for BCR-ABL

[rok vydání 2008, impact factor 2.358]